

### **REMARKS**

In an Office Action mailed March 1, 2007, claims 1, 26 and 38 – 40 were rejected and claims 2 – 25 and 28 were objected to. Claims 1-26, 28, and 38-40 are currently pending. An Information Disclosure Statement and references are provided.

#### **35 U.S.C. §112, 2<sup>nd</sup> paragraph**

Claim 26 was rejected under 35 U.S.C. § 112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner stated that the scope of the term "further comprising" is unclear. Claim 26 has been amended for clarification. Support for the amendment may be found the specification at page 7. Applicant respectfully requests withdrawal of the rejection of claim 26 under 35 U.S.C. § 112, 2<sup>nd</sup> paragraph.

#### **35 U.S.C. § 112, 1<sup>st</sup> paragraph**

Claims 1 was rejected under 35 U.S.C. § 112, first paragraph because the specification, while being enabling for compounds wherein X = NH or O, does not reasonably provide enablement for compounds wherein X =S(O)<sub>m</sub>. Claim 1 has been amended to recite compounds of formula (I) wherein X is NH or O. Support for the amendment to claim 1 may be found in the specification at pages 3 and 24 - 54.

Claims 1 and 26 were rejected under 35 U.S.C. § 112, first paragraph for failing to provide enablement for "physiological functional derivatives thereof." Claims 1 and 26 have been amended to recite salts and solvates. Support for the amendment to claims 1 and 26 is provided in the specification at pages 13 - 14.

Claims 38 – 40 were rejected under 35 U.S.C. § 112, first paragraph because the specification is not enabling for the prophylaxis of papovavirus or the treatment or prophylaxis of all oncogenic viruses such as adenoviruses and retroviruses.

Claims 38 – 40 were amended to recite treatment of papovavirus. Support for the amendment to claims 38 – 40 is provided in the specification at pages 20 – 21 and 55 – 56.

Applicants respectfully request withdrawal of the rejection of claims 1, 26, 38, 39, and 40 under 35 U.S.C. § 112, first paragraph.

#### Claim objections

Applicants submit that the amendment to claim 1 obviates the objection to claims 2 – 25 and 28.


Claim 15 has been amended to correct the typographical error in the word “compound.”

Claims 25 has been amended to correct the typographical error in the word “pyridine.”

Applicants respectfully submit that the present application is in condition for allowance. An early consideration and Notice of Allowance is earnestly solicited.

Applicants hereby request a 3-month extension of time to extend the response period up to and including September 1, 2007. The Commissioner is hereby authorized to charge such fees and any other fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,



Karen L. Prus  
Attorney for Applicant  
Registration No. 39,337

Date: *August 28, 2007*  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-2192  
Facsimile: 919-483-7988